Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada.

ABSTRACT:

Objectives

Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Here, we compare coronavirus disease 2019 (COVID-19) vaccine-induced antibody neutralization capacity in PWH vs. HIV-negative individuals following two vaccine doses.

Design

In Canadian prospective observational cohorts, including a multicentre study of PWH receiving at least two COVID-19 vaccinations (mRNA or ChAdOx1-S), and a parallel study of HIV-negative controls (Stop the Spread Ottawa Cohort), we measured vaccine-induced neutralization capacity 3 months post dose 2 (±1 month).

Methods

COVID-19 neutralization efficiency was measured by calculating the half maximal inhibitory dilution (ID50) using a high-throughput protein-based neutraliz

SUBMITTER: Costiniuk CT 

PROVIDER: S-EPMC10481923 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature